A Phase 1 Study to Evaluate the Effect of Nktr-102 for Injection (Etirinotecan Pegol) on the QT/QTC Interval in Patients With Advanced or Metastatic Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 26 Dec 2016
At a glance
- Drugs Etirinotecan pegol (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Nektar Therapeutics
- 20 Dec 2016 Status changed from active, no longer recruiting to completed.
- 26 Jul 2016 Status changed from recruiting to active, no longer recruiting.
- 26 Jul 2016 Planned End Date changed from 1 Apr 2016 to 1 Sep 2016.